163 related articles for article (PubMed ID: 29743517)
1. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs.
Gu S; Fu WY; Fu AKY; Tong EPS; Ip FCF; Huang X; Ip NY
Sci Rep; 2018 May; 8(1):7377. PubMed ID: 29743517
[TBL] [Abstract][Full Text] [Related]
2. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease.
Fu AK; Hung KW; Huang H; Gu S; Shen Y; Cheng EY; Ip FC; Huang X; Fu WY; Ip NY
Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9959-64. PubMed ID: 24958880
[TBL] [Abstract][Full Text] [Related]
3. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
4. EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease.
Poppe L; Rué L; Timmers M; Lenaerts A; Storm A; Callaerts-Vegh Z; Courtand G; de Boer A; Smolders S; Van Damme P; Van Den Bosch L; D'Hooge R; De Strooper B; Robberecht W; Lemmens R
Alzheimers Res Ther; 2019 Dec; 11(1):102. PubMed ID: 31831046
[TBL] [Abstract][Full Text] [Related]
5. Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology.
Rosenberger AF; Rozemuller AJ; van der Flier WM; Scheltens P; van der Vies SM; Hoozemans JJ
Acta Neuropathol Commun; 2014 Jul; 2():79. PubMed ID: 25027113
[TBL] [Abstract][Full Text] [Related]
6. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.
Lamberto I; Qin H; Noberini R; Premkumar L; Bourgin C; Riedl SJ; Song J; Pasquale EB
Biochem J; 2012 Jul; 445(1):47-56. PubMed ID: 22489865
[TBL] [Abstract][Full Text] [Related]
7. SORLA attenuates EphA4 signaling and amyloid β-induced neurodegeneration.
Huang TY; Zhao Y; Jiang LL; Li X; Liu Y; Sun Y; Piña-Crespo JC; Zhu B; Masliah E; Willnow TE; Pasquale EB; Xu H
J Exp Med; 2017 Dec; 214(12):3669-3685. PubMed ID: 29114064
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of Nanobodies targeting the EphA4 receptor.
Schoonaert L; Rué L; Roucourt B; Timmers M; Little S; Chávez-Gutiérrez L; Dewilde M; Joyce P; Curnock A; Weber P; Haustraete J; Hassanzadeh-Ghassabeh G; De Strooper B; Van Den Bosch L; Van Damme P; Lemmens R; Robberecht W
J Biol Chem; 2017 Jul; 292(27):11452-11465. PubMed ID: 28526745
[TBL] [Abstract][Full Text] [Related]
9. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
[TBL] [Abstract][Full Text] [Related]
10. EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-β oligomers.
Vargas LM; Leal N; Estrada LD; González A; Serrano F; Araya K; Gysling K; Inestrosa NC; Pasquale EB; Alvarez AR
PLoS One; 2014; 9(3):e92309. PubMed ID: 24658113
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols.
Noberini R; Koolpe M; Lamberto I; Pasquale EB
Pharmacol Res; 2012 Oct; 66(4):363-73. PubMed ID: 22750215
[TBL] [Abstract][Full Text] [Related]
12. miR-455-3p alleviates propofol-induced neurotoxicity by reducing EphA4 expression in developing neurons.
Zhu X; Li H; Tian M; Zhou S; He Y; Zhou M
Biomarkers; 2020 Dec; 25(8):685-692. PubMed ID: 33032457
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity.
Han X; Xu Y; Yang Y; Xi J; Tian W; Duggineni S; Huang Z; An J
PLoS One; 2013; 8(11):e80183. PubMed ID: 24265799
[TBL] [Abstract][Full Text] [Related]
14. EphA4 regulates Aβ production via BACE1 expression in neurons.
Tamura K; Chiu YW; Shiohara A; Hori Y; Tomita T
FASEB J; 2020 Dec; 34(12):16383-16396. PubMed ID: 33090569
[TBL] [Abstract][Full Text] [Related]
15. Potent and Selective EphA4 Agonists for the Treatment of ALS.
Wu B; De SK; Kulinich A; Salem AF; Koeppen J; Wang R; Barile E; Wang S; Zhang D; Ethell I; Pellecchia M
Cell Chem Biol; 2017 Mar; 24(3):293-305. PubMed ID: 28196613
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer's disease.
Vargas LM; Cerpa W; Muñoz FJ; Zanlungo S; Alvarez AR
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1148-1159. PubMed ID: 29378302
[TBL] [Abstract][Full Text] [Related]
17. Lipidation and PEGylation Strategies to Prolong the
Gomez-Soler M; Olson EJ; de la Torre ER; Zhao C; Lamberto I; Flood DT; Danho W; Lechtenberg BC; Riedl SJ; Dawson PE; Pasquale EB
Eur J Med Chem; 2023 Dec; 262():. PubMed ID: 38523699
[TBL] [Abstract][Full Text] [Related]
18. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
Qin H; Shi J; Noberini R; Pasquale EB; Song J
J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
[TBL] [Abstract][Full Text] [Related]
20. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis.
Ling KK; Jackson M; Alkam D; Liu D; Allaire N; Sun C; Kiaei M; McCampbell A; Rigo F
Neurobiol Dis; 2018 Jun; 114():174-183. PubMed ID: 29518482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
